Sonnet BioTherapeutics Holdings Inc
SONN
Market Cap$5.22M
Close$
$1.83
1.4% upside
Current Fair Value
1.4% upsideUndervalued by 1.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.22 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.0 |
| Outstanding Shares | 3,069,516 |
| Avg 30 Day Volume | 15,638 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Sonnet BioTherapeutics Holdings Inc
8 employees
CEO: Pankaj Mohan Founded in 2011, Sonnet Biotherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), th...